MLA
IMNM icon

MB, Levis & Associates’s Immunome IMNM Stock Holding History

MB, Levis & Associates’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.9K Hold
2,373
– – 0.02% 104
2025
Q4 		$51K Hold
2,373
– – 0.02% 103
2025
Q3 		$27.8K Hold
2,373
– – 0.01% 129
2025
Q2 		$22.1K Hold
2,373
– – 0.01% 163
2025
Q1 		$16K Hold
2,373
– – 0.01% 171
2024
Q4 		$25.2K Hold
2,373
– – 0.01% 149
2024
Q3 		$34.7K Hold
2,373
– – 0.02% 134
2024
Q2 		$28.7K Hold
2,373
– – 0.02% 143
2024
Q1 		$58.6K Hold
2,373
– – 0.03% 111
2023
Q4 		$25.4K Hold
2,373
– – 0.01% 145
2023
Q3 		$19.8K Hold
2,373
– – 0.01% 159
2023
Q2 		$18.8K Hold
2,373
– – 0.01% 162
2023
Q1 		$11.8K Hold
2,373
– – 0.01% 189
2022
Q4 		$5.24K Buy
+2,373
New +$9.56K ﹤0.01% 206

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

MB, Levis & Associates's IMNM Position: Q1 2026 in Review

MB, Levis & Associates held its Immunome (IMNM) position steady in Q1 2026 at 2,373 shares worth $51.9K. The position accounts for 0.02% of the portfolio, ranked #104.

MB, Levis & Associates first reported a position in IMNM in Q4 2022 and has held it in 14 quarters since. The position peaked at $58.6K in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • MB, Levis & Associates held 2,373 shares of Immunome worth $51.9K as of Q1 2026.
  • MB, Levis & Associates left its Immunome share count unchanged in Q1 2026.
  • Immunome made up 0.02% of MB, Levis & Associates's portfolio in Q1 2026, its #104 holding.
  • MB, Levis & Associates first reported a position in Immunome in Q4 2022 and has held it in 14 quarters since.
  • MB, Levis & Associates's Immunome position peaked at $58.6K in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on MB, Levis & Associates's 13F filing for Q1 2026, filed 8 Apr 2026.